Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (61353) 61353
Publication (5878) 5878
Newspaper Article (5224) 5224
Newsletter (3494) 3494
Book Review (476) 476
Book Chapter (210) 210
Trade Publication Article (188) 188
Magazine Article (168) 168
Book / eBook (132) 132
Report (112) 112
Web Resource (89) 89
Conference Proceeding (71) 71
Dissertation (54) 54
Transcript (34) 34
Data Set (17) 17
Government Document (11) 11
Reference (10) 10
Paper (2) 2
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (35170) 35170
animals (25996) 25996
female (25276) 25276
index medicus (24544) 24544
immunoglobulins (23165) 23165
male (20802) 20802
immunology (16332) 16332
mice (16286) 16286
adult (11044) 11044
middle aged (9605) 9605
proteins (7996) 7996
immunoglobulin g (7758) 7758
research (7217) 7217
antigens (6705) 6705
antibodies (6687) 6687
immunoglobulin g - blood (6612) 6612
mice, inbred balb c (6310) 6310
immunization (5938) 5938
vaccines (5891) 5891
research article (5714) 5714
health aspects (5700) 5700
aged (5667) 5667
medicine (5269) 5269
treatment outcome (5210) 5210
analysis (4938) 4938
adolescent (4914) 4914
vaccination (4590) 4590
child (4571) 4571
infections (4530) 4530
care and treatment (4395) 4395
disease (4391) 4391
infectious diseases (4318) 4318
medical research (4288) 4288
medicine, research & experimental (4268) 4268
enzyme-linked immunosorbent assay (4266) 4266
immunotherapy (4126) 4126
inflammation (4028) 4028
immunoglobulin g - immunology (4002) 4002
multidisciplinary sciences (3937) 3937
cytokines (3931) 3931
studies (3915) 3915
allergy (3861) 3861
rats (3859) 3859
patients (3795) 3795
immune response (3760) 3760
science (3701) 3701
disease models, animal (3666) 3666
oncology (3590) 3590
cancer (3552) 3552
immunoglobulin e (3502) 3502
time factors (3491) 3491
infection (3463) 3463
expression (3306) 3306
pharmacology & pharmacy (3297) 3297
lymphocytes (3293) 3293
child, preschool (3266) 3266
rodents (3260) 3260
children (3247) 3247
immune system (3233) 3233
mice, inbred c57bl (3150) 3150
administration, oral (3102) 3102
therapy (3080) 3080
clinical trials (3069) 3069
infant (2938) 2938
immunity (2929) 2929
immunoglobulin e - blood (2896) 2896
asthma (2890) 2890
monoclonal antibodies (2804) 2804
immunoglobulin g - administration & dosage (2782) 2782
microbiology (2779) 2779
hematology (2681) 2681
gene expression (2674) 2674
risk factors (2650) 2650
pediatrics (2641) 2641
pregnancy (2612) 2612
immunoglobulins, intravenous - therapeutic use (2611) 2611
viruses (2576) 2576
diagnosis (2426) 2426
apoptosis (2414) 2414
drug therapy (2409) 2409
immunoglobulin a (2380) 2380
immunoglobulins, intravenous - administration & dosage (2345) 2345
antibodies, monoclonal - therapeutic use (2337) 2337
laboratories (2337) 2337
cells (2326) 2326
antibodies, monoclonal - administration & dosage (2307) 2307
immunoglobulin g - biosynthesis (2299) 2299
immunoglobulin g - analysis (2281) 2281
physiological aspects (2281) 2281
tumors (2273) 2273
young adult (2244) 2244
dendritic cells (2149) 2149
immunogenicity (2140) 2140
immunoglobulin e - immunology (2140) 2140
article (2136) 2136
t cells (2128) 2128
prevention (2096) 2096
lymphocytes t (2094) 2094
dosage and administration (2072) 2072
medicine, general & internal (2071) 2071
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (102) 102
Online Resources - Online (10) 10
UofT at Scarborough - Stacks (6) 6
UTL at Downsview - May be requested (4) 4
UofT at Mississauga - Stacks (4) 4
Collection Dvlpm't (Acquisitions) - Closed Orders (3) 3
Engineering & Comp. Sci. - Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Earth Sciences (Noranda) - Stacks (1) 1
Gerstein Science - Closed Orders (1) 1
Robarts - Stacks (1) 1
Trinity College (John W Graham) - Stacks (1) 1
Women's College Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (67449) 67449
German (705) 705
Japanese (652) 652
French (529) 529
Russian (500) 500
Chinese (278) 278
Spanish (198) 198
Italian (162) 162
Polish (152) 152
Czech (62) 62
Danish (38) 38
Hungarian (36) 36
Korean (34) 34
Dutch (31) 31
Portuguese (23) 23
Norwegian (22) 22
Ukrainian (21) 21
Turkish (19) 19
Slovak (17) 17
Swedish (16) 16
Bulgarian (13) 13
Croatian (10) 10
Serbian (7) 7
Finnish (6) 6
Romanian (6) 6
Arabic (3) 3
Hebrew (3) 3
Urdu (2) 2
Bosnian (1) 1
Greek (1) 1
Lithuanian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation
by Ekberg, Henrik and Tedesco-Silva, Helio and Demirbas, Alper and Vítko, Štefan and Nashan, Björn and Gürkan, Alp and Margreiter, Raimund and Hugo, Christian and Grinyó, Josep M and Frei, Ulrich and Vanrenterghem, Yves and Daloze, Pierre and Halloran, Philip F and ELITE Symphony Study and ELITE-Symphony Study and Enheten för forskning kring njurfunktion och njursjukdom and Lund University and Renal Research Unit and Lunds universitet
The New England Journal of Medicine, ISSN 0028-4793, 12/2007, Volume 357, Issue 25, pp. 2562 - 2575
This study examines the toxicity of immunosuppressive regimens in renal-transplant recipients. A regimen containing mycophenolate mofetil, daclizumab, low-dose... 
MULTICENTER TRIAL | MEDICINE, GENERAL & INTERNAL | CYCLOSPORINE MICROEMULSION | EFFICACY | KIDNEY-TRANSPLANTATION | IMMUNOSUPPRESSION | ALLOGRAFT RECIPIENTS | TACROLIMUS | MYCOPHENOLATE-MOFETIL | SIROLIMUS | NEPHROTOXICITY | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Adrenal Cortex Hormones - therapeutic use | Enzyme Inhibitors - administration & dosage | Antibodies, Monoclonal, Humanized | Calcineurin Inhibitors | Treatment Failure | Adult | Diabetes Mellitus - etiology | Female | Drug Therapy, Combination | Mycophenolic Acid - administration & dosage | Immunosuppressive Agents - administration & dosage | Sirolimus - adverse effects | Tacrolimus - administration & dosage | Prednisone - administration & dosage | Glomerular Filtration Rate | Graft Rejection - prevention & control | Kaplan-Meier Estimate | Kidney Transplantation | Immunoglobulin G - administration & dosage | Opportunistic Infections | Sirolimus - administration & dosage | Mycophenolic Acid - analogs & derivatives | Antibodies, Monoclonal - administration & dosage | Cyclosporine - administration & dosage | Immunosuppressive Agents - adverse effects | Aged | Adrenal Cortex Hormones - administration & dosage | Transplantation | Corticosteroids | Kidneys | Research | Health aspects | Immunosuppressive agents | Medical research | Immunology | Inhibitor drugs | Transplants & implants | Toxicity | Inhibidors enzimàtics | Posologia | Ús terapèutic | Corticosteroides | Rebuig (Biologia) | Posology | Therapeutic use | Immunosupressive agents | Graft rejection | Trasplantament renal | Enzyme inhibitors | Adrenocortical hormones | Immunosupressors | Kidney transplantation | Tacrolimus: administration & dosage | Medical and Health Sciences | Graft Rejection: prevention & control | Immunoglobulin G: administration & dosage | Medicin och hälsovetenskap | Mycophenolic Acid: administration & dosage | Antibodies | Klinisk medicin | Monoclonal: administration & dosage | Prednisone: administration & dosage | Adrenal Cortex Hormones: administration & dosage | Immunosuppressive Agents: administration & dosage | Mycophenolic Acid: analogs & derivatives | Sirolimus: administration & dosage | Cyclosporine: administration & dosage | Calcineurin: antagonists & inhibitors | Diabetes Mellitus: etiology | Urologi och njurmedicin | Sirolimus: adverse effects | Adrenal Cortex Hormones: therapeutic use | Enzyme Inhibitors: administration & dosage | Immunosuppressive Agents: adverse effects | Clinical Medicine | Immunosuppressive Agents: therapeutic use | Urology and Nephrology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: The comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) Trial
by Gu, Youlan and Kampinga, Marthe and Wieringa, Wouter and Fokkema, Marieke and Nijsten, Maarten and Hillege, Hans and Heuvel, Ad and Tan, E.S and Pundziute, Gabija and Werf, Rik and Hoseyni Guyomi, Siyrous and Horst, Iwan and Zijlstra, Felix and Smet, Bart
Circulation (Baltimore), ISSN 0009-7322, 12/2010, Volume 122, Issue 25, pp. 2709 - 2717
textabstractBackground- Administration of the glycoprotein IIb/IIIa inhibitor abciximab is an effective adjunctive treatment strategy during primary... 
myocardial reperfusion | acute myocardial infarction | glycoproteins IIb-IIIa | angioplasty | DESIGN | CARDIAC & CARDIOVASCULAR SYSTEMS | METAANALYSIS | RATIONALE | RESOLUTION | INFUSION | PERIPHERAL VASCULAR DISEASE | BOLUS | PERFUSION | OUTCOMES | THROMBOLYTIC THERAPY | PRIMARY ANGIOPLASTY | Suction | Injections, Intravenous | Anticoagulants - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Immunoglobulin Fab Fragments - therapeutic use | Coronary Vessels | Myocardial Infarction - therapy | Myocardial Infarction - pathology | Endpoint Determination | Electrocardiography | Female | Myocardial Infarction - physiopathology | Thrombosis - therapy | Thrombosis - physiopathology | Angioplasty, Balloon, Coronary - methods | Anticoagulants - therapeutic use | Treatment Outcome | Combined Modality Therapy | Immunoglobulin Fab Fragments - administration & dosage | Antibodies, Monoclonal - administration & dosage | Aged | Myocardial Reperfusion Injury - prevention & control | Injections, Intra-Arterial
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction
by Van De Werf, Frans J and Assessment Safety Efficacy New Thr and Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators and Medicinska fakulteten and Medicinska och farmaceutiska vetenskapsområdet and Uppsala universitet and Institutionen för medicinska vetenskaper
The Lancet, ISSN 0140-6736, 08/2001, Volume 358, Issue 9282, pp. 605 - 613
Current fibrinolytic therapies fail to achieve optimum reperfusion in many patients. Low-molecular-weight heparins and platelet glycoprotein IIb/IIIa... 
MEDICINE, GENERAL & INTERNAL | THROMBOLYSIS | Recurrence | Humans | Middle Aged | Heparin - administration & dosage | Male | Tissue Plasminogen Activator - administration & dosage | Treatment Outcome | Chi-Square Distribution | Enoxaparin - administration & dosage | Immunoglobulin Fab Fragments - administration & dosage | Injections | Myocardial Infarction - drug therapy | Antibodies, Monoclonal - administration & dosage | Platelet Aggregation Inhibitors - administration & dosage | Survival Analysis | Female | Aged | Fibrinolytic Agents - administration & dosage | Drug Therapy, Combination | Dosage and administration | Thrombolytic drugs | Research | Tenecteplase | Drug therapy | Heart attack | Prevention | Evaluation | Ischemia | Enoxaparin | Reperfusion (Physiology) | Drug therapy, Combination | Heparin | Health aspects | Clinical trials | Heart attacks | Myocardial infarction | Coagulation | Hemorrhage | Bleeding | Infusion | Randomization | Reperfusion | Motivation | Blood platelets | Safety | Heparins | Anticoagulants | Stroke | Effectiveness | Complications | Mortality | Glycoprotein | Pharmacology | Patients | Trauma | Molecular chains | Studies | Fibrin | Monoclonal antibodies | Infarction | Heparin/administration & dosage | Medical and Health Sciences | Medicin och hälsovetenskap | Platelet Aggregation Inhibitors/administration & dosage | MEDICINE | Antibodies; Monoclonal/administration & dosage | Myocardial Infarction/drug therapy | Enoxaparin/administration & dosage | Tissue Plasminogen Activator/administration & dosage | Fibrinolytic Agents/administration & dosage | MEDICIN | Immunoglobulins; Fab/administration & dosage | Drug Therapy; Combination | Research Support; Non-U.S. Gov't
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)
by Wysham, Carol and Blevins, Thomas and Arakaki, Richard and Colon, Gildred and Garcia, Pedro and Atisso, Charles and Kuhstoss, Debra and Lakshmanan, Mark
Diabetes Care, ISSN 0149-5992, 2014, Volume 37, Issue 8, pp. 2159 - 2167
OBJECTIVE To compare the efficacy and safety of dulaglutide, a once-weekly GLP-1 receptor agonist, with placebo and exenatide in type 2 diabetic patients. The... 
GLYCEMIC CONTROL | GLUCAGON-LIKE PEPTIDE-1 | EXENDIN-4 | SITAGLIPTIN | ENDOCRINOLOGY & METABOLISM | ANALOG LIRAGLUTIDE | OPEN-LABEL | LY2189265 | TREATED PATIENTS | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Male | Immunoglobulin Fc Fragments - administration & dosage | Thiazolidinediones - administration & dosage | Metformin - adverse effects | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Venoms - administration & dosage | Female | Metformin - administration & dosage | Drug Therapy, Combination | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Drug Administration Schedule | Venoms - adverse effects | Hypoglycemia - drug therapy | Thiazolidinediones - adverse effects | Blood Glucose - drug effects | Glucagon-Like Peptides - adverse effects | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Peptides - adverse effects | Type 2 diabetes | Care and treatment | Safety and security measures | Dosage and administration | Metformin | Comparative analysis | Exenatide
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text How i treat Waldenström macroglobulinemia
by Treon, Steven P
Blood, ISSN 0006-4971, 08/2015, Volume 126, Issue 6, pp. 721 - 732
Waldenstrom macroglobulinemia (WM) is a B-cell neoplasm manifested by the accumulation of clonal immunoglobulin (Ig)M-secreting lymphoplasmacytic cells. MYD88... 
CONSENSUS PANEL RECOMMENDATIONS | 2ND INTERNATIONAL WORKSHOP | L265P SOMATIC MUTATION | MULTIPLE-MYELOMA | RITUXIMAB THERAPY | IMMUNOGLOBULIN-M | MYD88 L265P | LYMPHOPROLIFERATIVE DISORDERS | LYMPHOPLASMACYTIC CELLS | INHIBITOR EVEROLIMUS | HEMATOLOGY | Cyclophosphamide - administration & dosage | Nitrogen Mustard Compounds - administration & dosage | Waldenstrom Macroglobulinemia - therapy | Humans | Middle Aged | Pyrazines - administration & dosage | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Transplantation, Autologous | Molecular Targeted Therapy | Waldenstrom Macroglobulinemia - pathology | Adult | Receptors, CXCR4 - genetics | B-Lymphocytes - pathology | Boronic Acids - administration & dosage | Everolimus | B-Lymphocytes - metabolism | Waldenstrom Macroglobulinemia - diagnosis | Immunoglobulin M - genetics | Gene Expression | Genetic Predisposition to Disease | Sirolimus - analogs & derivatives | Bortezomib | Pyrimidines - administration & dosage | Myeloid Differentiation Factor 88 - genetics | Antineoplastic Combined Chemotherapy Protocols | Hematopoietic Stem Cell Transplantation | Rituximab | Vidarabine - analogs & derivatives | Cladribine - administration & dosage | Plasmapheresis | Receptors, CXCR4 - metabolism | B-Lymphocytes - drug effects | Sirolimus - administration & dosage | Pyrazoles - administration & dosage | Bendamustine Hydrochloride | Aged | Oligopeptides - administration & dosage | Vidarabine - administration & dosage | Myeloid Differentiation Factor 88 - metabolism | Waldenstrom Macroglobulinemia - genetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy
by Ravandi, Farhad and Jorgensen, Jeffrey L and Thomas, Deborah A and O'Brien, Susan and Garris, Rebecca and Faderl, Stefan and Huang, Xuelin and Wen, Sijin and Burger, Jan A and Ferrajoli, Alessandra and Kebriaei, Partow and Champlin, Richard E and Estrov, Zeev and Challagundla, Pramoda and Wang, Sa A and Luthra, Rajyalakshmi and Cortes, Jorge E and Kantarjian, Hagop M
Blood, ISSN 0006-4971, 08/2013, Volume 122, Issue 7, pp. 1214 - 1221
From 2001 to 2011, 122 patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia were treated with chemotherapy + imatinib (n... 
ADULT PATIENTS | HYPER-CVAD | GENE REARRANGEMENTS | STANDARD-RISK | QUANTIFICATION | ACUTE LYMPHOBLASTIC-LEUKEMIA | FLOW-CYTOMETRY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | MINIMAL RESIDUAL DISEASE | CLINICAL-SIGNIFICANCE | Piperazines - administration & dosage | Cyclophosphamide - administration & dosage | Prognosis | Follow-Up Studies | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Thiazoles - administration & dosage | Neoplasm Recurrence, Local - mortality | Young Adult | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Benzamides - administration & dosage | Flow Cytometry | Neoplasm, Residual - diagnosis | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Neoplasm, Residual - mortality | Philadelphia Chromosome | Real-Time Polymerase Chain Reaction | Doxorubicin - administration & dosage | Dasatinib | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Pyrimidines - administration & dosage | RNA, Messenger - genetics | Survival Rate | Reverse Transcriptase Polymerase Chain Reaction | Imatinib Mesylate | Remission Induction | Cytarabine - administration & dosage | Neoplasm, Residual - genetics | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Fusion Proteins, bcr-abl - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Methotrexate - administration & dosage | Neoplasm Recurrence, Local - genetics | Aged | Neoplasm Staging | Immunoglobulin Heavy Chains - genetics | Lymphoid Neoplasia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Administration of a probiotic with peanut oral immunotherapy: A randomized trial
by Tang, Mimi L.K., PhD and Ponsonby, Anne-Louise, PhD and Orsini, Francesca, MSc and Tey, Dean, FRACP and Robinson, Marnie, FRACP and Su, Ee Lyn, FRACP and Licciardi, Paul, PhD and Burks, Wesley, MD and Donath, Susan, MA
Journal of Allergy and Clinical Immunology, The, ISSN 0091-6749, 2014, Volume 135, Issue 3, pp. 737 - 744.e8
Background Coadministration of a bacterial adjuvant with oral immunotherapy (OIT) has been suggested as a potential treatment for food allergy. Objective To... 
Allergy and Immunology | peanut-specific IgE | probiotic | Peanut allergy | sustained unresponsiveness | oral immunotherapy | immune-modifying adjuvant | peanut-specific IgG4 | tolerance | desensitization | peanut-specific IgG | SUBLINGUAL ROUTE | TOLERANCE INDUCTION | FOOD ALLERGY | IGE | IMMUNOLOGY | CHILDREN | CHALLENGE | EGG ALLERGY | ALLERGY | PREDICTORS | INFANTS | COWS MILK ALLERGY | Arachis - chemistry | Probiotics - administration & dosage | Skin Tests | Double-Blind Method | Immunoglobulin G - blood | Administration, Oral | Humans | Child, Preschool | Infant | Male | Treatment Outcome | Peanut Hypersensitivity - immunology | Peanut Hypersensitivity - therapy | Immunoglobulin E - blood | Allergens - administration & dosage | Arachis - immunology | Peanut Hypersensitivity - physiopathology | Female | Child | Desensitization, Immunologic - methods | Pharmaceutical industry | Food allergy | Immunotherapy | Proteins | Studies | Food allergies | Probiotics | Pain | Peanuts | Clinical trials | Allergies | Abdomen | Food
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Corticosteroids for Guillain-Barré syndrome
by Hughes, Richard A. C and Brassington, Ruth and Gunn, Angela A and van Doorn, Pieter A
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 10/2016, Volume 2016, Issue 10, p. CD001446
Background Guillain-Barre syndrome (GBS) is an acute paralysing disease caused by inflammation of the peripheral nerves, which corticosteroids would be... 
GLOMERULONEPHRITIS | Methylprednisolone [administration & dosage; therapeutic use] | POLYNEUROPATHY | CONTROLLED-RANDOMIZED TRIAL | Humans | Prednisolone [administration & dosage; therapeutic use] | Adrenocorticotropic Hormone [administration & dosage;therapeutic use] | INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY | METHYLPREDNISOLONE | Guillain-Barre Syndrome [drug therapy] | Randomized Controlled Trials as Topic | MEDICINE, GENERAL & INTERNAL | PLASMA-EXCHANGE | PREDNISONE | EXPERIMENTAL ALLERGIC NEURITIS | STANDARD TREATMENT | INTRAVENOUS IMMUNOGLOBULIN | Anti-Inflammatory Agents [administration & dosage;therapeutic use] | Adult | Glucocorticoids [administration & dosage; therapeutic use] | Child | Glucocorticoids - administration & dosage | Glucocorticoids - therapeutic use | Prednisolone - administration & dosage | Methylprednisolone - therapeutic use | Adrenocorticotropic Hormone - therapeutic use | Guillain-Barre Syndrome - drug therapy | Adrenocorticotropic Hormone - administration & dosage | Anti-Inflammatory Agents - therapeutic use | Anti-Inflammatory Agents - administration & dosage | Prednisolone - therapeutic use | Methylprednisolone - administration & dosage
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Efficacy and safety of glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: A systematic review and mixed‐treatment comparison analysis
by Htike, Zin Z and Zaccardi, Francesco and Papamargaritis, Dimitris and Webb, David R and Khunti, Kamlesh and Davies, Melanie J
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 04/2017, Volume 19, Issue 4, pp. 524 - 536
Aims: To compare efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in people with type 2 diabetes. Materials and methods: We... 
GLP | type 2 diabetes | network meta‐analysis | systematic review | 1 analogue | network meta-analysis | GLP-1 analogue | GLYCEMIC CONTROL | EXENATIDE TWICE | ONCE-DAILY LIXISENATIDE | OPEN-LABEL | EUROPEAN ASSOCIATION | NETWORK METAANALYSIS | METFORMIN-TREATED PATIENTS | BASAL INSULIN | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | Glucagon-Like Peptide 1 - administration & dosage | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Glycated Hemoglobin A - drug effects | Male | Immunoglobulin Fc Fragments - administration & dosage | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Venoms - administration & dosage | Female | Hypoglycemia - chemically induced | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Drug Administration Schedule | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Treatment Outcome | Randomized Controlled Trials as Topic | Blood Glucose - drug effects | Glucagon-Like Peptides - adverse effects | Diabetes Mellitus, Type 2 - blood | Liraglutide - adverse effects | Incretins - adverse effects | Liraglutide - administration & dosage | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Glucagon-Like Peptide-1 Receptor - agonists | Incretins - administration & dosage | Peptides - adverse effects | Type 2 diabetes | Glycosylated hemoglobin | Glucagon | Analysis | Diabetes therapy | Hypoglycemia | Diabetes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text LC–MS/MS quantification of free and Fab-bound colchicine in plasma, urine and organs following colchicine administration and colchicine-specific Fab fragments treatment in Göttingen minipigs
by Fabresse, Nicolas and Allard, Julien and Sardaby, Marine and Thompson, Adrian and Clutton, R. Eddie and Eddleston, Michael and Alvarez, Jean-Claude
Journal of Chromatography B, ISSN 1570-0232, 08/2017, Volume 1060, pp. 400 - 406
Clinical evaluation of a colchicine specific antigen-binding fragment (Fab) in order to treat colchicine poisoning required the development of an accurate... 
Toxicology | Colchicine | Antidote | Mass spectrometry | Immunoglobulin Fab fragments | CLEARANCE | CHEMISTRY, ANALYTICAL | VOLUNTEERS | OVERDOSE | TISSUE | BIOCHEMICAL RESEARCH METHODS | REVERSAL | PHARMACOKINETICS | KINETICS | Limit of Detection | Reproducibility of Results | Colchicine - analysis | Colchicine - metabolism | Colchicine - administration & dosage | Immunoglobulin Fab Fragments - analysis | Linear Models | Tissue Distribution | Animals | Immunoglobulin Fab Fragments - metabolism | Swine | Immunoglobulin Fab Fragments - chemistry | Swine, Miniature | Chromatography, Liquid - methods | Tandem Mass Spectrometry - methods | Colchicine - chemistry | Proteins | Antigens | Analysis | Denaturation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights